Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease
A Phase 1/2 Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic and Preliminary Efficacy of BMN 701 (GILT-tagged Recombinant Human GAA) in Patients With Late-onset Pompe Disease
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Adelaide, SA
-
Adelaide, Adelaide, SA, Australien, 5006
- Royal Adelaide Hospital, SA Pathology
-
-
-
-
-
Birmingham, Det Forenede Kongerige, B15 2TH
- Old Queen Elizabeth Hospital, Department of Medicine
-
London, Det Forenede Kongerige, NW3 2QG
- Royal Free Hospital
-
Salford, Det Forenede Kongerige, M6 8HD
- Salford Royal Hospital NHS Trust
-
-
-
-
California
-
La Jolla, California, Forenede Stater, 92103-8765
- Univ of California San Diego School of Medicine
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32610
- University of Florida College of Medicine
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- University of Kansas Medical Center
-
-
-
-
-
Nice, Frankrig, 06202
- Hôpital de I´Archet- Centre Hospitalier Universitaire Nice
-
Paris Cedex 13, Frankrig, 75651
- Hôpital Pitié-Salpêtrière
-
-
-
-
Rheinland-pfalz
-
Mainz, Rheinland-pfalz, Tyskland, 55131
- Zentrum für Kinder- und Jugenmedizin
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria:
- Patient has been diagnosed with Pompe Disease prior to or during the screening period based on 2 GAA gene mutations and either: endogenous GAA activity <75% of the lower limit of the normal adult range reported by the testing laboratory, as assessed in cultured skin fibroblasts -or- endogenous GAA activity <75% of the lower limit of the normal adult range reported by the testing laboratory, as assessed by dried blood spot or whole blood assay;
- Patient is male or female and 13 years of age or older at the time of enrollment in the study;
- Sexually active patients must be willing to use an acceptable method of contraception while participating in the study and for at least 4 months following the last dose of BMN 701;
- If patient is female and not considered to be of childbearing potential, she is at least 2 years post-menopausal or had tubal ligation at least 1 year prior to screening, or who have had total hysterectomy;
- If patient is female and of childbearing potential, she has negative urine pregnancy tests during the Screening Period and at the Baseline visit and be willing to have additional pregnancy tests during the study;
- Patient has ≥30% predicted upright FVC and either <80% predicted upright FVC, or >10% reduction in supine FVC compared to upright FVC during the Screening Period;
- Patient is naïve to Enzyme Replacement Therapy (ERT) with rhGAA;
- Patient must be able to ambulate at least 40 meters (131.2 feet) on the 6MWT conducted at the Screening visit (use of assistive devices such as walker, cane, or crutches, is permitted); and
- If subject was female, she was not lactating
Exclusion criteria:
- Patient has a history of diabetes or other disease known to cause hypoglycemia and is currently receiving, or might anticipate receiving, hypoglycemic agents during the course of the study;
- Patient has been on any immunosuppressive medication other than glucocorticosteroids within 1 year prior to enrollment into this study;
- Patient requires invasive ventilatory assistance at the time of enrollment into the study;
- Patient has received any investigational medication within 30 days prior to the first dose of study drug or is scheduled to receive any investigational drug other than BMN 701 during the course of the study;
- Patient has previously been admitted to the study;
- Patient is breastfeeding at screening or planning to become pregnant (self or partner) at any time during the study;
- Patient has a medical condition or extenuating circumstance that, in the opinion of the Investigator, might compromise the patient's ability to comply with the protocol requirements or compromise the patient's well being or safety;
- Patient has any condition that, in the view of the Investigator, places the patient at high risk of poor treatment compliance or of not completing the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: BMN 701
IV infusion
|
GILT-mærket rekombinant human GAA
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Adverse Events
Tidsramme: 24 weeks
|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
|
24 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Six Minutes Walk Test
Tidsramme: Baseline up to 24 weeks
|
Change from Baseline in Six Minutes Walk Test.
The 6MWT measured the maximum distance the subject could walk on a flat, hard surface in a period of 6 minutes
|
Baseline up to 24 weeks
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Percent Predicted Upright Forced Vital Capacity
Tidsramme: Baseline up to 24 week
|
Change from Baseline in Percent Predicted Upright Forced Vital Capacity.
Changes in respiratory function were assessed by measurement of MEP, MIP and MVV; and percent predicted upright and supine FVC.
|
Baseline up to 24 week
|
|
Change From Baseline in Percent Predicted Supine Forced Vital Capacity
Tidsramme: Baseline up to 24 weeks
|
Change from Baseline in Percent Predicted Supine Forced Vital Capacity.
Changes in respiratory function were assessed by measurement of MEP, MIP and MVV; and percent predicted upright and supine FVC.
|
Baseline up to 24 weeks
|
|
Change From Baseline in Percent Predicted Upright Maximum Expiratory Pressure
Tidsramme: Baseline up to 24 weeks
|
Change from Baseline in Percent Predicted Upright Maximum Expiratory Pressure.
Changes in respiratory function were assessed by measurement of MEP, MIP and MVV; and percent predicted upright and supine FVC.
|
Baseline up to 24 weeks
|
|
Change From Baseline in Percent Predicted Upright Maximum Inspiratory Pressure
Tidsramme: Baseline up to 24 weeks
|
Change from Baseline in Percent Predicted Upright Maximum Inspiratory Pressure.
Changes in respiratory function were assessed by measurement of MEP, MIP and MVV; and percent predicted upright and supine FVC.
|
Baseline up to 24 weeks
|
|
Change From Baseline in Upright Maximum Ventilatory Volume
Tidsramme: Baseline up to 24 weeks
|
Change from Baseline in Upright Maximum Ventilatory Volume.
Changes in respiratory function were assessed by measurement of MEP, MIP and MVV; and percent predicted upright and supine FVC.
|
Baseline up to 24 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Medical Monitor, BioMarin Pharmaceutical
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Metaboliske sygdomme
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Genetiske sygdomme, medfødte
- Kulhydratmetabolisme, medfødte fejl
- Metabolisme, medfødte fejl
- Lysosomale opbevaringssygdomme
- Hjernesygdomme, metaboliske
- Hjernesygdomme, metaboliske, medfødte
- Lysosomale opbevaringssygdomme, nervesystemet
- Glykogenopbevaringssygdom
- Glykogenopbevaringssygdom type II
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- POM-001
- 2010-023561-22 (EudraCT nummer)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .